



Comprehensive Anaesthetic Management of Parturient Women with Peripartum Cardiomyopathy: A Multidisciplinary Approach

¹Dr Sudheer Pratap Godara, ²Dr Abrar Dhaifallah, ³Dr Alma Alfakhori, ⁴Dr Juhi Godara

¹Specialist Anaesthesiology Rashid Hospital, Dubai

²Year 5 student, Dubai medical college, Dubai

³Year 5 student, Dubai medical college, Dubai

⁴Specialist obstetrics and gynecology, Dubai hospital, Dubai

Corresponding Author: Dr Sudheer Pratap Godara, Specialist Anaesthesiology Rashid Hospital, Dubai

(Received: 14 June 2024

Revised: 01 July 2024

Accepted: 18 August 2024)

KEYWORDS

Peripartum
Cardiomyopathy,
Anesthetic
Management,
Maternal Care,
Multidisciplinary
Approach, Pregnancy,
Cardiac Anesthesia,
Hemodynamic
Stability

ABSTRACT:

Background:

Peripartum cardiomyopathy (PPCM) is an extreme type of coronary heart failure that occurs during the 9th month of pregnancy or up to 5 months after delivery; it imposes stern requirements for anesthetic management. This narrative bibliography aims towards an updated source of knowledge on the anesthetic concerns and the handling techniques for the parturient ladies diagnosed with PPCM particularly hoping to enhance the maternal as well as the fetal outcomes through interdisciplinary care.

Objectives:

To identify the primary issues in the peripartum period, which involves two sections including the assessment in peripartum period following evaluation of present guidelines and improvement in present enhancements of outcomes in discipline of anesthesiology and cardiology regarding PPCM.

Methods:

A specific literature review was conducted in the area of research, scientific initiatives and professional opinions up to and including 2024. Health information databases including PubMed, Scopus, as well as current medical guidelines have been systematically searched to obtain the most updated information on the management of PPCM.

Results:

The review identifies important steps for the control of PPCM, inclusive of:

1. Preoperative Assessment: Concentrating on comprehensive cardiologic appraisal, including with the help of a cross-functional team, echo-cardiography, serum and biomarkers analysis and comprehensive records ad Infinitum.
2. Anesthetic Strategies: Subcutaneous and general anesthesia seem to be less advantageous compared to regional anesthesia, since the latter helps maintain the patient's blood pressure levels. This paper presents various speculations on approving the relief of exertions pupils 'analgesia and probing the decision-making process regarding the mode of delivery.
3. Intraoperative and Postpartum Management: Suggestions for further patient surveillance and monitoring of the volume of fluid status as well as recommendations concerning the use of inotropes and vasopressors. Stemming from postpartum care, initial risks inclusive of arrhythmias and coronary heart failure deterioration is detected early with follow-ups provided by both the cardiologists and obstetricians.

Conclusion:

Hence, the use of this optimised approach to parturient ladies with PPCM involves a mixed research, advanced Cardiac Care alongwith anesthetic perception to follow an evidence based approach. It is crucial to admit that future research should address existing deficiencies in information, primarily, the creation of new therapeutic approaches and the use of effective monitoring tools to increase patients 'outcomes.

Introduction

Peripartum cardiomyopathy (PPCM) is defined as the onset of heart failure in the last month of pregnancy to five months postpartum when no other recognized causes like Coronary Artery Disease (CAD), significant valvular

disease or Congenital Heart Disease (CHD) exist¹ This condition raises several difficulties in the practice of obstetric and anesthetic care because of the sudden onset, clinical signs that are life-threatening to the mother and



the baby, and the crucial requirement of an early and accurate interdisciplinary approach.

The occurrence of PPCM is not uniform across countries and is categorized between 1/1000-1/4000 of all live births; however, developed countries have established a higher ratio due to high prevalence of hypertension and malnutrition². Research show that, PPCM impacts about 0.14% of the pregnancies in the United States, though; there is disparity among the races and ethnicities. Research revealed that African-American women are most vulnerable where incidence rates could be as high as five times the figure recorded in Caucasian women³. The other associated risk factors include past history of preeclampsia, family history of cardiomyopathy and parous women particularly those who are multigravida⁴.

In terms of the disease's mechanism, genetics, autoimmunity, and viruses are presumed to be major determinants, though its precise nature remains elusive. The titin gene (TTN) associated with animal and human myocardial structure and function mutations have been identified as well as the adrenoceptor beta-1 gene (ADRB1) affecting myocardial contractility and heart rate regulation. Such genetic changes indicate the hereditary, and with precursors related to viral illnesses or autoimmune disturbance⁵. Further, inflammation plays a crucial role in PPCM development since biochemical analysis of the affected individuals' blood often reveals high levels of TNF- α and IL-6 cytokines⁶. Such immune activation results in myocardial inflammation, apoptosis, and progressive ventricular dysfunction worsening the clinical picture of PPCM. PPCM may cause symptoms related to heart failure, which include dyspnea, fatigue, peripheral oedema, and hepatic dysfunction with features of congestion, such as ascites⁷. By far the most significant amount of data in diagnosing PPCM will involve an echocardiographic documentation of left ventricular systolic dysfunction, which involves an LVEF of below 45%, with rule out of other cardiomyopathies⁸. Plasma or serum BNP or NT-proBNP is useful in both diagnosing and monitoring the severity of PPCM since increased levels correlate with the severity of heart failure⁹.

Additional applications of advanced imaging algorithms, like cardiac MRI, to evaluate myocardial viability and extent of fibrosis are beneficial in determining prognosis and therapeutic management. Particular attention should be paid to the assessment of PPCM patients before the surgery to ensure proper cardiac function and minimize

perioperative complications. The aspects of this assessment are collection of clinical data and history, the physical examination, and detailed echocardiographic examination of ventricular function and diastolic properties. Heart failure severity can be measured by the help of biomarkers, mainly BNP and NT-proBNP⁹. The patient's individualized management plan should involve a team made up of obstetrician, cardiologist, and anesthesiologist. This plan should include risk-stratification, optimisation of cardiac therapy, and what should be done in the event of complications. In addition, specific interventions focused on the optimization of PPCM include optimizing the patient's fluid balance, titrating heart failure medications, and counseling patients about the risks that are associated with pregnancy and delivery¹⁰.

The decision for anesthesia in PPCM should ensure adequate care is taken in handling a patient's cardiac state¹¹. Regional anesthesia especially epidural or combined spinal-epidural anesthesia is commonly used because of its effect of decreasing sympathetic tone and myocardial oxygen demand thus reducing the risk of myocardial ischemia. But, it should be used judiciously so that sympathetic blockage is not overdone and there is no hypotension. If regional anesthesia is putting off or not feasible, then, general anesthesia should be administered with special regard for the doctor's rapid sequence induction to avoid aspiration. Achieving and maintaining a stable blood pressure and cardiac output is essential for the patient utilising vasopressors and inotropes namely dobutamine or norepinephrine during the induction and maintenance phases¹².

It is recommended to monitor the client's rate and rhythm of cardiac function during the intraoperative period. Standard continuous and intermittent monitoring consist of electrocardiography, non-invasive blood pressure, pulse oximetry and capnography or end-tidal CO₂¹³. Other complicated signs, which may include invasive arterial lines as well as CVP that is utilized in management of fluids together with cardiac filling pressures¹⁴.

Hemodynamics management consist of efforts to maintain the optimum balance of fluids that will not overload the heart yet will fill the heart enough to pump enough blood. Specifically, inotropes and vasopressors are given to optimize cardiac output¹², and systemic vascular resistance that is essential in stabilizing many patient's hemodynamics.



The postpartum period represents another sensitive phase of PPCM patients' life since they experience higher levels of cardiac loads resulting from the reduction in blood volumes and changing hormones. It is recommended that the mother should be closely monitored in the early period after giving birth by maintaining electrocardiogram, the use of heart failure treatments as well as close observation of the patient for the development of complications such as arrhythmias and thromboembolism. Follow-up management entails serial echocardiography in the assessment of ventricular function and periodic monitoring of biomarkers as a check of the status of heart failure. Exercise testing and exercise training, together with lifestyle changes, are crucial in the cardiac rehabilitation as it is aimed at improving the general cardiovascular status and functional capacity¹⁵. Education regarding future pregnancies is critical as it includes talks on recurrence risks and the conception of a new plan for birth control.

The ACOG and AHA guidelines present quite a comprehensive reference for the management of PPCM¹⁶. It should be noted that early recognition of HF, the participation of numerous specialists, and the implementation of GDMT are key in these guidelines. Therapies include ACE inhibitors, beta-blockers, and diuretics to enhance cardiac function; and the monitoring of the mother's and fetus's status during pregnancy and in the postpartum period¹⁷. This is in relation to the guidelines that require development of patient-specific care plans due to the diverse risks and characteristics of each PPCM patient.

The management of parturient women with PPCM is a arduous task because it must consider the pregnancy physiology and cardiac pathology. The cardiovascular system of pregnant women changes in the course of pregnancy, and the increase in blood volume, cardiac output, and heart rate can worsen the PPCM patients' condition¹⁸. Consequently, anesthetic care of the pregnant woman must be well-coordinated and planned to avoid alteration of the maternal and fetal hemodynamic stability and cardiotoxic effect on the heart.

Proper management requires inputs from an Obstetrician, a cardiologist and an anesthesiologist all working as a team¹⁹. This is to reduce risks that are associated with anesthesia and surgery and which include regional anesthesia, proper fluid balance and high risk monitoring. Newer developments in managing cardiac diseases and

administration of anesthesia present possibilities of enhancing the results of the critically ill and higher risk patients. Thus, this review intends to expand on these strategies and present up-to-date information on their applicability by identifying directions for further research and enhancement of parturient affected women's care.

Materials and Methods

This review is based on a comprehensive analysis of current literature, clinical guidelines, and expert opinions regarding the anesthetic management of parturient women with peripartum cardiomyopathy (PPCM). The methodology for this review is detailed below:

Literature Search

Databases and Sources:

A systematic literature search was conducted using the following databases:

- PubMed
- Scopus
- Cochrane Library
- Google Scholar

Search Terms:

Key search terms included:

- "Peripartum cardiomyopathy"
- "PPCM"
- "Anesthetic management"
- "Cardiac anesthesia"
- "Pregnancy"
- "Maternal outcomes"
- "Fetal outcomes"
- "Regional anesthesia"
- "General anesthesia"
- "Inotropic support"
- "Hemodynamic monitoring"

Data Extraction and Synthesis

Study Selection:

Two reviewers independently screened titles and abstracts for relevance. Full-text articles were then assessed for



eligibility based on the inclusion and exclusion criteria. Discrepancies were resolved through discussion and consensus.

Data Extraction:

Relevant data were extracted using a standardized form, including:

- Study design
- Population characteristics
- Anesthetic techniques used
- Hemodynamic monitoring methods
- Pharmacologic interventions
- Maternal and fetal outcomes
- Key findings and conclusions

Data Synthesis:

Data were synthesized qualitatively to provide a narrative summary of current practices, challenges, and recommendations in the anesthetic management of PPCM. Comparative analysis of different anesthetic techniques and monitoring strategies was performed to highlight their relative advantages and limitations.

Quality Assessment

The quality of included studies was assessed using the following criteria:

- Methodological rigor
- Sample size
- Validity and reliability of measurement tools
- Clarity and completeness of reporting
- Potential for bias

Clinical Guidelines:

Current clinical guidelines and consensus statements from reputable medical organizations, such as the American College of Obstetricians and Gynecologists (ACOG), the American Heart Association (AHA), and the Society for Obstetric Anesthesia and Perinatology (SOAP), were reviewed to align the findings with standard clinical practices.

Expert Opinions:

Consultations with experts in cardiology, anesthesiology, and maternal-fetal medicine were conducted to validate

the findings and provide insights into emerging trends and challenges in the management of PPCM.

Descriptive Statistics:

Descriptive statistics were used to summarize the characteristics of the study populations, anesthetic techniques, and outcomes.

Discussion

PPCM poses numerous problems for anesthetic management because of its sudden onset and the extent of the cardiac involvement it causes²⁰. While it is crucial to maintain mothers' hemodynamic stability, there is also a need to avoid any harm to the fetus, which makes the process very fragile, and therefore requiring synergy involving multidisciplinary personnel.

For Parturient women with PPCM, regional anesthesia, epidural and spinal; techniques in particular, are most preferable as it can help maintain haemodynamic stability and excludes respiratory and cardiovascular depressant effect of general anesthesia. Research has also confirmed that regional anesthesia is safe in PPCM patients and offers satisfactory clinical outcomes²¹.

On that account one of the significant benefits of regional anesthesia is its capacity to supply adequate analgesia and anesthesia when the patient's systemic exposure to drug is limited and this will be of great importance in cases such as PPCM where the heart's functionality is altered²². In a key study, Iddrisu M et al showed that regional anesthesia was safe mainly due to lesser incidence of severe hypotension and requirement of vasopressors as compared with general anaesthesia²³. This is important because managing PPCM calls for ensuring that the patient's blood pressure does not shoot; hence, vasopressor use should not hike myocardial oxygen demand.

According to epidemiologic studies, specific groups of patients are more susceptible to PPCM such as the African American women who are at a higher risk of experiencing the worst effects of general anesthesia because of hypertension and obesity. African-American women in particular have PPCM risks ranging from 3 to 5 times of that of Caucasian women which supports the opinion that anesthetic management should be based on the risk of the patient²⁴.

General anaesthesia though may sometimes be required, is hazardous to PPCM's patients²⁵. The agents used in the induction as well as maintenance of general anesthesia are



known to affect myocardial contractility and hence result in hemodynamic compromise. Research done on patients with PPCM confirmed general anesthesia increases the risk of cardiovascular incidents, especially hypotension and arrhythmia compared to other groups of patients²⁶.

For instance, Wolfe et al studied patient's outcomes who were admitted with PPCM, requiring a cesarean section under general anesthesia and reported higher intraoperative complications than those in patients who received regional anesthesia²⁷. This work underlined the necessity of the increased focus on the hemodynamic monitoring and the possibility of intensive intervention in case of the patients under general anesthesia.

To the molecular level, the myocardial effect of general anesthetics can be detrimental in PPCM because of the already compromised functioning of the left ventricle. Some of the inhalational agents and intravenous anesthetics produce direct influence on myocardial contractility and systemic vascular resistance (SVR) and thus, potentially worsen cardiac dysfunction²⁸. This means that there must always be a modulation of the anesthetic agents and constant observation of the patient's hemodynamic status to avoid this.

Comparing this noted data between the two techniques signifies to support regional anesthesia rather than the general one in PPCM patients because of the relatively fewer cardiotoxic effects and better control of hemodynamic factors²⁹.

The combined spinal-epidural anesthesia (CSE) is one of the most useful techniques in anesthetic management of parturient women with PPCM. This technique is characterized by fast induction of spinal anesthesia and focuses on the possibility to regulate the level of analgesia and anesthesia carefully like in epidural anesthesia³⁰. Different authors, comparing CSE with other methods of patient positioning during labor, pointed out several merits of CSE in PPCM patients due to the ability to provide stable hemodynamics and the best maternal and fetal outcomes³¹.

CSE enables the administration of adequate anesthesia and analgesia in a relatively shorter duration this is important during the process of labor and delivery in the clients with PPCM. The spinal component gives a concentrated mass that is needed for adequate analgesia while, on the other hand the epidural aspect enables postoperative modulation of the degree of anesthesia in

accord to patient's condition³². This dynamic control is proved to be extremely effective in the prevention of the cardiovascular changes of PPCM, for example, in the regulation of blood pressure, dampening the effect of sympathetic nervous system³³.

For example, meta-analysis by Svircevic et al have illustrated that compared to the conventional epidural or general anesthesia techniques CSE has been proved to be useful in reducing rate of the perioperative cardiovascular complications³⁴. This reduced complication is due to the fact that CSE can deliver specific anesthesia with less amount of local anesthetic agents, hence reducing the impact on cardiac status.

CSE's pharmacokinetics and pharmacodynamics have been investigated on local anesthetics used in CSE involving PPCM patient's myocardial function³⁵. Persistent peripheral nerve blocks are generally obtained by local anaesthetics like bupivacaine and ropivacaine; the latter interferes with sodium channels in the peripheral nerves and light up nerve impulse conduction and blocks the sensory and motor operations. The sources report that the degree of myocardial contractility is reduced in patients with PPCM and thereby ventricular systolic function, which makes it important to control the level of local anesthetics penetrated into the blood trough systemic absorption in order to prevent the toxic effects caused by their interaction with the cardiac tissue.

These comparisons have indicated that CSE allows better control on the depth and duration of anesthesia than using an epidural or a spinal one alone³⁶. This precise control also minimizes the chances of causing harm to the whole body and making corrections when the health of the mother or fetus is declining. Metabolic, as well as the mechanism of the elimination, of the local anesthetic has played an essential role in the designing of dosing regimens that will reduce cardiovascular complications while enhancing the efficacy of the drug in the management of acute pain³⁷.

The comparative data seems to justify the preference for combined spinal-epidural anesthesia in PPCM patients because of its capacity for maintaining a suitable hemodynamics status, sufficient pain relief as well as non-systemic impact on the cardiac function.

Preoperative preparation is crucial in PPCM management, and this involves assessing the patient's individual risk factors. To achieve this, one needs to look at possible risk



factors and preferably, address them or at least know their management; secondly, to control the patient's cardiovascular status in order to prevent a critical situation; third, to devise an anesthetic plan which would minimally harm the patient and the fetus³⁸. This section focuses on the essential planning measures aimed at preoperative preparation and driven by epidemic and molecular findings.

Assessment before surgery in the patients with PPCM includes a comprehensive cardiologic evaluation to detect the severity of LVEF reduction and presence of other factors that may affect anesthetic planning³⁸. Echocardiography is a key component of this evaluation by furnishing specifics of LVEF, chamber size, and others in regards to congenital or acquired abnormalities. Patients with an LVEF below 45% are found to be at higher risk during the perioperative period, required hence, closer monitoring and intervention measures³⁹.

Apart from echocardiography, the assessment of serum biomarkers involves tissue characterization and using plasma brain natriuretic peptide (BNP) and N-terminal pro B-type natriuretic peptide (NT-proBNP). Increased levels of these markers reflect myocardial stress and severity of heart failure on patients; thus, risk stratification can be done on patients in order to come up with proper clinical interventions in the event of adverse outcomes. Chao et al in their study also established the fact that high BNP levels in PPCM patients are likely to predict poor survival outcomes thus meaning that biomarker assessment should be part of preoperative planning⁴⁰.

Risk Stratification and Interdisciplinary Collaboration: Risk Stratification and Interdisciplinary Collaboration:

Risk stratification in PPCM refers to the process of evaluating the degree of cardiac dysfunction and the presence of other complicating factors in PPCM. This stratification determines the degree of preoperative preparation and intraoperative care that will be needed. Patients with severely reduced LVEF or severe arrhythmias or known thromboembolic disorders are best managed in conjunction with cardiologist, anesthesiologist and obstetrician where the plan of individual patient will be discussed and coordinated.

Demographic features were shown to matter as evaluated by the epidemiologic data regarding the risk stratification. For example, PPCM appears to be more serious in African

American women as compared with Caucasian women, suggesting that a more stringent preoperative preparatory process may be necessary since black women have more known comorbid conditions like high blood pressure or diabetes⁴¹. Other studies pointed out that the design of risk stratification systems should be based used separate clinical and demographic characteristics in order to optimize the prognosis in this risk group.

Pharmacologic care of PPCM patients with reference to preoperative optimization is a paramount factor to reckon. Administration of beta blockers, ACE inhibitors and diuretics is usual in order to control cardiac function and minimize pre and after load. However, one needs to take particular care in managing these medicines and their impact of teratogenic effects specially in the post second trimester of pregnancy. Kim et al have used beta-blockers particularly carvedilol to improve the cardiac function and also reduce the signs of PPCM patients⁴².

The favorable outcomes of beta-blockers in treating PPCM are independent of down regulation of adrenergic receptors and therefore decreased myocardial oxygen demand⁴³. Research has found, polymorphisms of ADRB1 that affect the treatment by beta-blocker therapy⁴⁴; these finding underline the potential for application of the concept of pharmacogenomics in optimizing of medication.

Optimization of the preoperative status and risk assessment is important in anesthetic management of women with PPCM. Pregnant woman with cardiac diseases require detailed cardiologic evaluation according to clinical and demographic risk factors and pharmaceutical management to reduce maternal and perinatal morbidity and mortality⁴⁵.

Management of PPCM parturient women during surgery is important because the Obstetric Anaesthetists' Association recommends that the parturient's standing blood pressure should be reduced by 10- 15% during labour and delivery⁴⁶. Strategies that work center on managing maternal heart rate and rhythm, anesthesia management and protection of the mother and the baby.

PPCM patients require monitoring of hemodynamic parameters intraoperatively and hence advanced hemodynamic monitoring should be done. Supervision of vital signs like the heart rate, blood pressure, CVP and, arterial oxygen saturation must be done in the most continuous manner⁴⁷. Such invasive procedures as acute



arterial line and central venous catheterism offers real-time information, and, thus, allows for early identification of the hemodynamic compromise. The studies, for instance Loreto M and others, show that invasive hemodynamic monitoring for PPCM women who are managed through cesarean sections successfully augments the patients' outcomes by delivering detailed hemodynamic information which leads to early intercessions⁴⁸. Objective monitoring allows the changes in the rate of fluid administration, the degree of inotropic support, and anesthetic plane to ensure the stabilization of hemodynamics.

Epidural anesthesia is chosen for PPCM patients because these patients need to have stable hemodynamics and because general anesthesia will decrease insulin production by the liver. Epidural anesthesia or combined spinal-epidural anesthesia are able to produce good analgesia and at the same time give the anesthetist precise control of the depth of anesthesia. Similar to a research conducted by Shatalin et al., the use of regional techniques was demonstrated to be linked with lesser perioperative cardiovascular complications as well as superior maternal and fetal results compared to general anesthesia^{48,49}. Systemically, local anesthetic agents administered in smaller controlled quantities mitigate on the occurrence of toxic effects together with adverse myocardial impacts.

When Regional anesthesia might be contraindicated or have failed; general anesthesia may be required. The choice and method of induction of anesthesia should be slow and cautious since the procedure involves soon to be gynecological surgical patients. It is advised to use nonhypotensive agents such as etomidate and ketamine whereas the usage of agents like propofol and thiopental that causes significant hypotension should not be employed⁵⁰.

Due to decreased function of the myocardial derived from PPCM, there may be the need to use inotropic agents to improve the cardiac output. These agents increase contractility of cardiac muscles while at the same time not increasing the quantity of oxygen required by the muscles. A number of cases may need vasopressors such as norepinephrine to ensure adequate perfusion pressure especially when the anesthetized patient has had vasodilation⁵¹. Research based on molecular biology reveals that the inotropic and vasopressor agents are receptor selective in their action and primarily enhance the function of the heart's chambers and blood vessels, hence

can be more effectively beneficial when applied to PPCM patients.

Another important part of intraoperative care in PPCM is the management of intraoperative volume status²⁰. The objective is to achieve the best value of preload that will not lead to fluid collection that could worsen the status of heart failure. The balance of needing both adequate hydration and staunch hemostasis can be maintained in intravenous fluid therapy through correct calculation of amounts administered, with the help of monitoring patient's haemodynamic status. The dosage of colloids or crystalloids depends with the patient's volume status and continuing hemorrhage⁵².

Epidemiologic data demonstrate that there is disparity in how institutions manage fluids to persons at the end of life and show the importance of using evidence-based information on how to manage the fluid⁵³. A multicenter study indicated compliance with the recommended guidelines on fluid management as a means of enhancing PPCM patient status⁵⁴.

A proper follow-up plan focusing on PPCM patients significantly reduces emergent complications and contributes to proper functioning of the cardiovascular system⁵⁵. The first immediate period concerns itself with looking at areas of complication such as arrhythmias, new acute heart failure exacerbations and hemorrhages. This is well observed when the patient is in a monitored facility, preferably a Cardiac Intensive Care Unit (CICU) to aid in early identification of these complications⁵⁶. Being able to continuously monitor the patient's hemodynamics and repeating the markers at regular intervals will help to evaluate the outcome of the treatment conducted and will also provide further tactics for therapy⁵⁷.

The pharmaceutical treatment in the postpartum period is initiated with the help of medications, which are aimed at stabilizing the patient's cardiac condition and avoiding further deterioration of the disease. Beta-blockers such as metoprolol, carvedilol are some of the beginning choices as they also have the capacity to decrease the myocardial oxygen demand and enhance left ventricular function⁵⁸. Neurohormonal activation can also be treated using ACE inhibitors or ARBs also work to support the management of the ventricular remodeling⁵⁹. It essential to monitor for side effects like hypotension and renal dysfunction when the treatment is being started and when the dosage is being adjusted⁶⁰.



The cardiac function needs to be evaluated routinely to observe any symptoms of relapse of PPCM and to monitor other associated conditions. Follow-up echocardiography that usually takes every 3-6 months during the first years allows to control LVEF and observe eventual worsening of the ventricular function⁶¹. Supervising of cardiac enzymes offers more data with respect to the target myocardial traction and helps to make appropriate changes in the therapy⁶².

Since PPCM has been suspected to have genetic predisibility, it is advised that genetic counseling and screening in the family should be undertaken⁶². Familial tendencies may be determined genetic variations including titin (TTN) or Adrenoceptor beta-1 (ADRB1) that will enable the physician to devise specific treatment plans⁶³. The monitoring of first-degree relatives especially women of affected patients enable early diagnosis and intervention if suspicion or diagnosis of PPCM is realized⁶⁴.

PPCM can significantly affect patients and their families at both the psychological and social levels because it stems from heart failure, which occurs at an ill-timed period. Counseling expert and Psychological enablement is an important component of patient care, and covers issues of anxiety, depression, and adaptation to the illness. Peer-to-peer and family support groups and disease education can enhance the patients and families' methods of dealing with disease and lead to better quality of life.

Conclusion

Current and future investigations in PPCM centre on its aetiopathogenesis, discovery of new markers of the disease, and directed treatments. Experimental research for PPCM remains to reveal new gene traits and immunoprofiles relevant to PPCM and promising for precision medicine. Because of differences in patients' demographics and the severity of the illness the large trials should be conducted on multi-centric basis to confirm the existing strategies of the management and establish the patient-specific recommendations.

References :

- Ziccardi MR, Siddique MS. Peripartum cardiomyopathy [Internet]. StatPearls - NCBI Bookshelf. 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482185>
- Ballard LC, Cois A, Kea B. Peripartum Cardiomyopathy: a Review. *Current Emergency and Hospital Medicine Reports* [Internet]. 2019 Jul 22;7(3):127–34. Available from: <https://doi.org/10.1007/s40138-019-00192-3>
- Robbins LS, Szychowski JM, Nassel A, Arora G, Armour EK, Walker Z, et al. Geographic disparities in peripartum cardiomyopathy outcomes. *American Journal of Obstetrics & Gynecology MFM* [Internet]. 2023 Feb 1;5(2):100788. Available from: <https://doi.org/10.1016/j.ajogmf.2022.100788>
- Sethi D, Kumar N. Peripartum cardiomyopathy with preeclampsia in a parturient: A case report with literature review. *Turkish Journal of Emergency Medicine* [Internet]. 2020 Jan 1;20(4):202. Available from: <https://doi.org/10.4103/2452-2473.297467>
- Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. *Clinical Reviews in Allergy & Immunology* [Internet]. 2002 Jan 1;23(3):301–24. Available from: <https://doi.org/10.1385/criai:23:3:301>
- Kryczka K, Demkow M, Dzielińska Z. Biomarkers in Peripartum Cardiomyopathy—What we know and what is still to be found. *Biomolecules* [Internet]. 2024 Jan 12;14(1):103. Available from: <https://doi.org/10.3390/biom14010103>
- Azibani F, Sliwa K. Peripartum Cardiomyopathy: an Update. *Current Heart Failure Reports* [Internet]. 2018 Jul 26;15(5):297–306. Available from: <https://doi.org/10.1007/s11897-018-0404-x>
- Iorgoveanu C, Zaghoul A, Ashwath M. Peripartum cardiomyopathy: a review. *Heart Failure Reviews* [Internet]. 2021 Jun 17;26(6):1287–96. Available from: <https://doi.org/10.1007/s10741-020-10061-x>
- Esbrand FD, Zafar S, Panthangi V, Kurupp ARC, Raju A, Luthra G, et al. Utility of NT-ProBNP in the diagnosis and Prognosis of Pregnancy Associated Cardiovascular Conditions: a Systematic review. *Cureus* [Internet]. 2022 Dec 22; Available from: <https://doi.org/10.7759/cureus.32848>
- Afari H, Sheehan M, Reza N. Contemporary management of cardiomyopathy and heart failure in pregnancy. *Cardiology and Therapy* [Internet]. 2024



- Feb 10; Available from: <https://doi.org/10.1007/s40119-024-00351-y>
11. Patil V. Anaesthetic management in peripartum cardiomyopathy. *Journal of Anesthesia & Intensive Care Medicine* [Internet]. 2018 Mar 20;6(1). Available from: <https://doi.org/10.19080/jaicm.2018.06.555677>
 12. VanValkinburgh D, Kerndt CC, Hashmi MF. Inotropes and vasopressors [Internet]. StatPearls - NCBI Bookshelf. 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482411>
 13. Khanna AK, Banga A, Rigdon J, White BN, Cuvillier C, Ferraz J, et al. Role of continuous pulse oximetry and capnography monitoring in the prevention of postoperative respiratory failure, postoperative opioid-induced respiratory depression and adverse outcomes on hospital wards: A systematic review and meta-analysis. *Journal of Clinical Anesthesia* [Internet]. 2024 Jun 1;94:111374. Available from: <https://doi.org/10.1016/j.jclinane.2024.111374>
 14. Lata I, Gupta R, Sahu S, Singh H. Emergency management of decompensated peripartum cardiomyopathy. *Journal of Emergencies Trauma and Shock* [Internet]. 2009 Jan 1;2(2):124. Available from: <https://doi.org/10.4103/0974-2700.50748>
 15. Taylor RS, Dalal HM, McDonagh STJ. The role of cardiac rehabilitation in improving cardiovascular outcomes. *Nature Reviews Cardiology* [Internet]. 2021 Sep 16;19(3):180–94. Available from: <https://doi.org/10.1038/s41569-021-00611-7>
 16. Park K, Merz CNB, Bello NA, Davis M, Duvernoy C, Elgendy IY, et al. Management of women with acquired cardiovascular disease from Pre-Conception through pregnancy and postpartum. *Journal of the American College of Cardiology* [Internet]. 2021 Apr 1;77(14):1799–812. Available from: <https://doi.org/10.1016/j.jacc.2021.01.057>
 17. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy. *Journal of the American College of Cardiology* [Internet]. 2020 Jan 1;75(2):207–21. Available from: <https://doi.org/10.1016/j.jacc.2019.11.014>
 18. Iftikhar SF, Biswas M. Cardiac Disease in Pregnancy. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024
 19. Arendt KW, Lindley KJ. Obstetric anesthesia management of the patient with cardiac disease. *International Journal of Obstetric Anesthesia* [Internet]. 2019 Feb 1;37:73–85. Available from: <https://doi.org/10.1016/j.ijoa.2018.09.011>
 20. Trikha A, Ramachandran R, Rewari V. Anaesthetic management of patients with peripartum cardiomyopathy. *Journal of Obstetric Anaesthesia and Critical Care* [Internet]. 2011 Jan 1;1(1):5. Available from: <https://doi.org/10.4103/2249-4472.84249>
 21. Juneja R, Nambiar P. Cardiomyopathies and anaesthesia. *Indian Journal of Anaesthesia* [Internet]. 2017 Jan 1;61(9):728. Available from: https://doi.org/10.4103/ija.ija_385_17
 22. Dohlman L, Kwikiriza A, Ehie O. Benefits and Barriers to increasing regional anesthesia in Resource-Limited Settings. *Local and Regional Anesthesia* [Internet]. 2020 Oct 1;Volume 13:147–58. Available from: <https://doi.org/10.2147/lra.s236550>
 23. Iddrisu M, Khan ZH. Anesthesia for cesarean delivery: general or regional anesthesia—a systematic review. *Ain-Shams Journal of Anaesthesiology* [Internet]. 2021 Jan 6;13(1). Available from: <https://doi.org/10.1186/s42077-020-00121-7>
 24. Abel WM, Spikes T, Greer DB. A qualitative study. *The Journal of Cardiovascular Nursing* [Internet]. 2020 Nov 4;36(2):96–103. Available from: <https://doi.org/10.1097/jcn.0000000000000759>
 25. Peripartum Cardiomyopathy: Review of the Literature [Internet]. Vol. 48, *Yonsei Med J*. 2007 p. 731–47. Available from: <https://ymj.kr/Synapse/Data/PDFData/0069YMJ/ymj-48-731.pdf>
 26. Sharma M, Ninave S, Chandak A, Chandak V. Anaesthetic management of a peripartum cardiomyopathy patient undergoing caesarean section. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH* [Internet]. 2022 Jan 1; Available from: <https://doi.org/10.7860/jcdr/2022/57272.16775>



27. Wolfe DS, Liu C, Alboucai J, Karten A, Mushi J, Yellin S, et al. Maternal Outcomes in Women with Peripartum Cardiomyopathy versus Age and Race-Matched Peers in an Urban US Community. *Journal of Cardiovascular Development and Disease* [Internet]. 2022 Aug 6;9(8):250. Available from: <https://doi.org/10.3390/jcdd9080250>
28. Elkayam U, Goland S, Pieper PG, Silversides CK. High-Risk cardiac disease in pregnancy. *Journal of the American College of Cardiology* [Internet]. 2016 Jul 1;68(4):396–410. Available from: <https://doi.org/10.1016/j.jacc.2016.05.048>
29. Simmons SW, Taghizadeh N, Dennis AT, Hughes D, Cyna AM. Combined spinal-epidural versus epidural analgesia in labour. *Cochrane Library* [Internet]. 2012 Oct 17; Available from: <https://doi.org/10.1002/14651858.cd003401.pub3>
30. Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, et al. Part 12: Cardiac arrest in special situations. *Circulation* [Internet]. 2010 Nov 2;122(18_suppl_3). Available from: <https://doi.org/10.1161/circulationaha.110.971069>
31. Katz JA, Bridenbaugh PO, Knarr DC, Helton SH, Denson DD. Pharmacodynamics and pharmacokinetics of epidural ropivacaine in humans. *Anesthesia & Analgesia* [Internet]. 1990 Jan 1;70(1):167–21. Available from: <https://doi.org/10.1213/0000539-199001000-00004>
32. Burm AGL. Clinical Pharmacokinetics of epidural and spinal anaesthesia. *Clinical Pharmacokinetics* [Internet]. 1989 May 1;16(5):283–311. Available from: <https://doi.org/10.2165/00003088-198916050-00002>
33. Biteker M, Kayata S K, Duman D, Turkmen M, Bozkurt B. Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. *Current Cardiology Reviews* [Internet]. 2014 Jul 31;10(4):317–26. Available from: <https://doi.org/10.2174/1573403x10666140320144048>
34. Svircevic V, Van Dijk D, Nierich A, Passier M, Kalkman C, Van Der Heijden G, et al. Meta-analysis of thoracic epidural anesthesia versus general anesthesia for cardiac surgery [Internet]. *Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews - NCBI Bookshelf*. 2011. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK81448/>
35. Shnaider R, Ezri T, Szmuk P, Larson S, Wartens RD, Katz J. Combined spinal-epidural anesthesia for Cesarean section in a patient with peripartum dilated cardiomyopathy. *Canadian Journal of Anesthesia/Journal Canadien D Anesthésie* [Internet]. 2001 Jul 1;48(7):681–3. Available from: <https://doi.org/10.1007/bf03016203>
36. Ibrahim IR, Sharma V. Cardiomyopathy and anaesthesia. *BJA Education* [Internet]. 2017 Nov 1;17(11):363–9. Available from: <https://doi.org/10.1093/bjaed/mkx022>
37. Bourne E, Wright C, Royse C. A review of local anesthetic cardiotoxicity and treatment with lipid emulsion. *Local and Regional Anesthesia* [Internet]. 2010 Feb 1;11. Available from: <https://doi.org/10.2147/lra.s8814>
38. Kawamoto Y, Nishihara T, Aono J, Nandate H, Hamada T, Yasuoka T, et al. Perioperative management of emergent cesarean section in a patient with peripartum cardiomyopathy and orthopnea: a case report. *Journal of International Medical Research* [Internet]. 2021 Dec 1;49(12):030006052110630. Available from: <https://doi.org/10.1177/03000605211063077>
39. Kosaraju A, Goyal A, Grigorova Y, Makaryus AN. Left ventricular ejection fraction [Internet]. *StatPearls - NCBI Bookshelf*. 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459131/>
40. Cao N, Jia N, Zhu N. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. *International Journal of Molecular Sciences* [Internet]. 2019 Apr 12;20(8):1820. Available from: <https://doi.org/10.3390/ijms20081820>
41. Irizarry OC, Levine LD, Lewey J, Boyer T, Riis V, Elovitz MA, et al. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and Non-African American women. *JAMA Cardiology* [Internet]. 2017 Nov 1;2(11):1256. Available from: <https://doi.org/10.1001/jamacardio.2017.3574>



42. Kim MJ, Shin MS. Practical management of peripartum cardiomyopathy. *The Korean Journal of Internal Medicine* [Internet]. 2017 May 1;32(3):393–403. Available from: <https://doi.org/10.3904/kjim.2016.360>
43. Koenig T, Bauersachs J, Hilfiker-Kleiner D. Bromocriptine for the treatment of peripartum cardiomyopathy. *Cardiac Failure Review* [Internet]. 2018 Jan 1;4(1):1. Available from: <https://doi.org/10.15420/cfr.2018:2:2>
44. Fayed MS, Saleh MA, Sabri NA, Elkholy AA. β 1-adrenergic receptor polymorphisms: a possible genetic predictor of bisoprolol response in acute coronary syndrome. *Future Science OA* [Internet]. 2023 Dec 1;9(10). Available from: <https://doi.org/10.2144/fsoa-2023-0113>
45. Sahu AK, Harsha MM, Rathoor S. Cardiovascular Diseases in Pregnancy - A brief overview. *Current Cardiology Reviews* [Internet]. 2022 Jan 1;18(1). Available from: <https://doi.org/10.2174/1573403x17666210825103653>
46. Maronge L, Bogod D. Complications in obstetric anaesthesia. *Anaesthesia* [Internet]. 2018 Jan 1;73(S1):61–6. Available from: <https://doi.org/10.1111/anae.14141>
47. Huygh J, Peeters Y, Bernards J, Malbrain MLNG. Hemodynamic monitoring in the critically ill: an overview of current cardiac output monitoring methods. *F1000Research* [Internet]. 2016 Dec 16;5:2855. Available from: <https://doi.org/10.12688/f1000research.8991.1>
48. Loreto M, Pisanti M, Celentani M, Pasta G, Erman A, Santangelo C, et al. Non invasive hemodynamic monitoring for fluids and blood resuscitation during placenta praevia accreta cesarean delivery: a retrospective observational study. *Journal of Anesthesia Analgesia and Critical Care* [Internet]. 2022 Dec 27;2(1). Available from: <https://doi.org/10.1186/s44158-022-00083-2>
49. Shatalin D, Jaber M, Barsky D, Avitan T, Grisaru-Granovsky S, Gozal Y, et al. Outcome of Peripartum Anesthesia in Women with Valvular Disease. *PubMed* [Internet]. 2020 Jul 1;27(1):11–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/34056118>
50. Wan C, Hanson AC, Schulte PJ, Dong Y, Bauer PR. Propofol, ketamine, and etomidate as induction agents for intubation and outcomes in critically ill patients: a retrospective cohort study. *Critical Care Explorations* [Internet]. 2021 May 1;3(5):e0435. Available from: <https://doi.org/10.1097/cce.0000000000000435>
51. Martin GS, Bassett P. Crystalloids vs. colloids for fluid resuscitation in the Intensive Care Unit: A systematic review and meta-analysis. *Journal of Critical Care* [Internet]. 2019 Apr 1;50:144–54. Available from: <https://doi.org/10.1016/j.jcrc.2018.11.031>
52. Masip JM, Toledano LA, Martínez SF, Roig MDG. Massive postpartum hemorrhage: protocol and red code. In: *InTech eBooks* [Internet]. 2017. Available from: <https://doi.org/10.5772/intechopen.69968>
53. Castera MR, Borhade MB. Fluid management [Internet]. *StatPearls - NCBI Bookshelf*. 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK532305/>
54. Crozier T. Fluid management in the complicated OBS patient. *The Global Library of Women S Medicine* [Internet]. 2021 Jan 1; Available from: <https://doi.org/10.3843/glowm.413243>
55. Carlson S, Schultz J, Ramu B, Davis MB. Peripartum cardiomyopathy: Risks Diagnosis and management. *Journal of Multidisciplinary Healthcare* [Internet]. 2023 May 1;Volume 16:1249–58. Available from: <https://doi.org/10.2147/jmdh.s372747>
56. Dinic V, Markovic D, Savic N, Kutlesic M, Jankovic RJ. Peripartum cardiomyopathy in Intensive Care unit: an update. *Frontiers in Medicine* [Internet]. 2015 Nov 23;2. Available from: <https://doi.org/10.3389/fmed.2015.00082>
57. Okeke T, Ezenyeaku C, Ikeako L. Peripartum cardiomyopathy. *Annals of Medical and Health Sciences Research* [Internet]. 2013 Jan 1;3(3):313. Available from: <https://doi.org/10.4103/2141-9248.117925>
58. Martinez A, Lakkimsetti M, Maharjan S, Aslam MA, Basnyat A, Kafley S, et al. Beta-Blockers and their current role in maternal and neonatal health: A Narrative Review of the literature. *Cureus* [Internet].



2023 Aug 24; Available from:
<https://doi.org/10.7759/cureus.44043>

59. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. *Nature Reviews Cardiology* [Internet]. 2016 Oct 6;14(1):30–8. Available from:
<https://doi.org/10.1038/nrcardio.2016.163>
60. Kearney L, Wright P, Fhadil S, Thomas M. Postpartum cardiomyopathy and considerations for breastfeeding. *Cardiac Failure Review* [Internet]. 2018 Jan 1;4(2):112. Available from:
<https://doi.org/10.15420/cfr.2018.21.2>
61. Kiran GR, RajKumar C, Chandrasekhar P. Clinical and echocardiographic predictors of outcomes in patients with peripartum cardiomyopathy: A single centre, six month follow-up study. *Indian Heart Journal* [Internet]. 2021 May 1;73(3):319–24. Available from:
<https://doi.org/10.1016/j.ihj.2021.01.009>
62. Basit H, Huecker MR. Myocardial infarction serum markers [Internet]. StatPearls - NCBI Bookshelf. 2023. Available from:
<https://www.ncbi.nlm.nih.gov/books/NBK532966/>
63. Arany Z. It is time to offer genetic testing to women with peripartum cardiomyopathy. *Circulation* [Internet]. 2022 Jul 5;146(1):4–5. Available from:
<https://doi.org/10.1161/circulationaha.122.059177>
64. Canpolat U, Çetin EH, Yayla Ç, Aras D. Familial occurrence of peripartum cardiomyopathy: Genetic origin, unrecognized dilated cardiomyopathy or chance effect? *Journal of Cardiology Cases* [Internet]. 2015 Oct 1;12(4):101–3. Available from:
<https://doi.org/10.1016/j.jccase.2015.05.002>